Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Thalidomide has shown promise as an adjunct therapy for β-thalassaemia, yet its effectiveness and safety are uncertain. This systematic review and meta-analysis evaluate the efficacy and safety of thalidomide in β-thalassaemia; in both transfusion-dependent and non-transfusion-dependent patients. Scopus, PubMed and Cochrane databases were searched for studies assessing the efficacy and safety of thalidomide in β-thalassaemia.
Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9 (PCSK9). The comparison of Inclisiran with statin versus statin alone in ORION-10 trial demonstrated significant reductions in low-density lipoprotein cholesterol (LDL-C). Our study explored the price of Inclisiran at which cost-effectiveness is achieved for secondary prevention of cardiovascular events from the Australian healthcare perspective.
K. Perera N. Kam Z. Ademi D. Liew E. Zomer Bempedoic acid is a novel adenosine triphosphate (ATP) citrate lyase inhibitor. The Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen (CLEAR) Harmony trial demonstrated that bempedoic acid, in addition to statin therapy, significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients at high risk of cardiovascular disease (CVD).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
